Jazz EVP sells 6,907 shares after option exercise
Jazz Pharmaceuticals executive Samantha Pearce reported an exercise-and-sale transaction in company stock.
Rhea-AI Filing Summary
Jazz Pharmaceuticals executive Samantha Pearce reported an exercise-and-sale transaction in company stock. On May 28, 2026, the EVP, Chief Commercial Officer exercised non-qualified stock options to acquire 6,907 ordinary shares at an exercise price of $109.45 per share and sold 6,907 ordinary shares in an open-market transaction at $235.41 per share. Following these transactions, she directly owns 50,272 ordinary shares. The exercised options were granted under the company’s 2011 Equity Incentive Plan and had fully vested by March 2, 2024, and this specific option grant is now fully exercised.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 6,907 shares ($870K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Pearce Samantha
Role
EVP, Chief Commercial Officer
Sold
6,907 shs ($1.63M)
Approx. gross sale proceeds
$1.63M
Approx. exercise cost
$756K
Approx. pre-tax spread
$870K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 6,907 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 6,907 | $109.45 | $756K |
| Sale | Ordinary Shares | 6,907 | $235.41 | $1.63M |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Ordinary Shares — 50,272 shares (Direct)
Footnotes (1)
- F1. These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vested in 36 equal monthly installments thereafter. The option was fully vested as of March 2, 2024.
Key Figures
Shares sold: 6,907 shares
Sale price per share: $235.41 per share
Shares acquired via exercise: 6,907 shares
+3 more
6 metrics
Shares sold
6,907 shares
Open-market sale of ordinary shares on May 28, 2026
Sale price per share
$235.41 per share
Price for 6,907 ordinary shares sold May 28, 2026
Shares acquired via exercise
6,907 shares
Ordinary shares from non-qualified stock option exercise
Option exercise price
$109.45 per share
Non-qualified stock option exercise price for 6,907 shares
Shares owned after transaction
50,272 shares
Direct ownership of ordinary shares after May 28, 2026
Option expiration date
May 6, 2030
Expiration for the non-qualified stock option grant exercised
Key Terms
Non-Qualified Stock Option, open-market sale, 2011 Equity Incentive Plan, vested, +1 more
5 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
2011 Equity Incentive Plan financial
"These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan."
vested financial
"The option was fully vested as of March 2, 2024."
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jazz Pharmaceuticals (JAZZ) executive Samantha Pearce report?
Samantha Pearce reported an exercise-and-sale transaction involving 6,907 Jazz Pharmaceuticals ordinary shares. She exercised non-qualified stock options at $109.45 per share and sold 6,907 shares at $235.41 per share in an open-market transaction on May 28, 2026.
At what price did Samantha Pearce exercise her Jazz Pharmaceuticals stock options?
She exercised non-qualified stock options at an exercise price of $109.45 per Jazz Pharmaceuticals ordinary share. These options covered 6,907 shares, were granted under the 2011 Equity Incentive Plan, and were fully vested as of March 2, 2024 before the reported exercise.
What happened to the specific stock option grant disclosed in Samantha Pearce’s Jazz Pharmaceuticals Form 4?
The non-qualified stock option grant for 6,907 shares was fully exercised, leaving zero options remaining from that grant. It had an exercise price of $109.45 per share, was granted under the 2011 Equity Incentive Plan, and was fully vested by March 2, 2024.
Under which plan were Samantha Pearce’s exercised Jazz Pharmaceuticals options granted?
The exercised options were granted under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan. They covered 6,907 ordinary shares, vested over four years from a March 2, 2020 vesting commencement date, and were fully vested as of March 2, 2024 before the exercise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
